Tamtam Try Tamtam free
Charles River Laboratories logo

Charles River Laboratories account plan

Patients Animal Planet People

At a glance

Charles River Laboratories is a non-clinical drug development partner: research models, safety testing and QC; FY2025 revenue $4.02 billion.

Charles River Laboratories (NYSE: CRL), based in Wilmington, Massachusetts, is a full-service, non-clinical drug development partner. It supplies research models, discovery and regulated safety assessment services and manufacturing quality-control testing to pharma, biotech, medical device and other clients, from over 120 sites in over 20 countries. FY2025 revenue was $4,015.4 million (down 0.9%), with GAAP operating income of $25.2 million after impairments and a net loss to shareholders of $144.3 million. It had approximately 19,700 employees at December 27, 2025. Birgit Girshick succeeded James C. Foster as CEO in May 2026.

Business units

Strategic priorities

Pathway to Purpose strategy
Presented at the September 24, 2026 Investor Day: modernise the company, strengthen the scientific portfolio, and deliver a client-centric approach.
Create the Future savings
Over $300 million of cumulative savings from 2027 through 2030 through simpler processes, automation, digital enablement and AI-assisted tools, on top of about $300 million cumulative annualized savings by end-2026; 500 initiatives are under way.
Grow bioanalysis
Bioanalysis revenue is expected to grow at a high-single-digit CAGR to approximately $450 million in 2030, with five organic capacity expansions and the Frontage acquisition.
2030 financial targets
5%-7% organic revenue CAGR for 2027-2030, a non-GAAP operating margin of about 24% and low-double-digit non-GAAP EPS CAGR.
Secure NHP supply
With K.F. Cambodia and Noveprim, roughly 80% of estimated NHP usage is covered by the company's own farms.
Simplify the portfolio
Divest non-core assets of about 7% of 2025 revenue (done in May 2026) and reinvest in the core through acquisitions, partnerships and internal investment.

Latest results

In Q3 2026 (quarter ended September 26, 2026) revenue was $982.7 million, down 2.2% reported because of the May 2026 divestitures, but organic growth was 4.7% against an outlook of 1%-3%. GAAP operating income rose to $202.6 million (20.6% margin vs 13.3%) and non-GAAP EPS was $3.09, up 27.2%. DSA net bookings rose 32% to $652 million and backlog reached $2.03 billion. The company raised 2026 guidance to organic growth of at least 1.5% and non-GAAP EPS of $11.35-$11.55, and expects a gradual improvement in 2027.

Investments and deals

Frontage bioanalysis and DMPK acquisition
Agreed November 9, 2026: Frontage's Exton, Pennsylvania operations for approximately $470 million in cash plus up to $75 million of contingent payments, approximately 340 employees, closing expected in the first half of 2027.
K.F. Cambodia NHP supplier
Assets acquired January 14, 2026 at a preliminary price of $507.3 million, vertically integrating NHP supply for DSA.
PathoQuest
Remaining 79% bought on April 17, 2026 for $67.4 million: next-generation sequencing for biologics quality control, reported in Manufacturing.
Divestitures
European Discovery Services sold to IQVIA for $126.4 million (May 22, 2026); CDMO and Cell Solutions sold to GI Partners (May 6, 2026).
Automation and Apollo platform
A fully automated Endosafe cartridge suite increased production capacity by 14%; the Apollo cloud platform serves more than 18,000 client users.

Challenges and risks

New approach methodologies
The FDA's April 2025 plan to reduce animal testing and the U.K. roadmap to phase it out could reduce demand for some products and services.
Weak RMS demand
Academic and government clients are nearly 40% of RMS revenue; CRADL has not returned to growth because new biotech starts have not recovered.
Pricing pressure
Discounting is being reduced only modestly, with no major benefit expected before the second half of 2027.
Impairments and portfolio losses
2025 included a $165.0 million Biologics Solutions goodwill impairment; the CDMO and Cell Solutions sale generated $181.7 million of losses over nine months of 2026.
Biotech and government funding
Demand depends on biotech funding and government R&D funding, which the 10-K names as key risks.

What leadership says

“Our focus is to simplify the company and move faster, invest where we can win, and continue to lead as the scientific partner of choice for the critical work that our clients do.”

Birgit Girshick, Chief Executive Officer · Q3 2026 earnings call, November 4, 2026

“The planned acquisition accelerates our strategy to expand our bioanalysis capabilities and enhance our offering in an attractive, high-growth market.”

Birgit Girshick, Chief Executive Officer · Frontage acquisition press release, November 9, 2026

“we view AI as an enabling technology to support our work over a long term and to complement it, but we do not see it as a disruptor.”

James C. Foster, former Chair and CEO · Q4 and full-year 2025 earnings call, February 18, 2026

“We have currently enough supply to meet our long-range financial targets”

Birgit Girshick, Chief Executive Officer · On NHP supply, Q3 2026 earnings call, November 4, 2026

Where a supplier can help

Automation and digitisation for Create the Future
The savings programme relies on automation, digital enablement and AI-assisted tools; vendors of lab automation and workflow software fit directly.
Bioanalysis capacity build-out
Five organic bioanalysis expansions and the Frontage integration create needs for lab equipment, facilities work and integration services.
Procurement and global business services
Procurement synergies, global business services and real-estate rationalisation are named savings levers, opening doors for outsourcing and procurement partners.
NAMs and in vitro testing
Investment in in vitro testing and NAMs such as virtual control groups needs data, software and assay technology partners.
Client-facing digital tools
Expanding the Apollo platform to more clients and segments points to demand for e-commerce, data and client portal technology.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Charles River Laboratories?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Charles River Laboratories

What does Charles River Laboratories do?

It supports drug development before clinical trials: research models, discovery and safety assessment services, and quality-control testing for drug manufacturing.

What is Charles River's revenue?

FY2025 revenue was $4,015.4 million; Q3 2026 revenue was $982.7 million.

How many employees does Charles River have?

Approximately 19,700 employees at December 27, 2025.

Who leads Charles River Laboratories?

Birgit Girshick has been CEO since May 2026, succeeding James C. Foster; Glenn Coleman is EVP and CFO.

What is Charles River's strategy?

Pathway to Purpose: modernise operations through the Create the Future savings programme, invest in bioanalysis and in vitro testing, and serve clients with a client-centric approach, targeting 5%-7% organic growth from 2027 to 2030.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)